Touyun Biotech Group Limited (HKG:1332)
Hong Kong · Delayed Price · Currency is HKD 0.1270
+0.0050 (4.10%)
Feb 13, 2026, 3:58 PM HKT
Touyun Biotech Group Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 142.68 | 152.3 | 198.03 | 323.33 | 292.39 | 218.81 |
Other Revenue | 0.93 | 7.67 | 0.61 | -7.51 | -8.88 | -12.03 |
| 143.61 | 159.97 | 198.64 | 315.83 | 283.51 | 206.79 | |
Revenue Growth (YoY) | 0.32% | -19.47% | -37.10% | 11.40% | 37.10% | -39.66% |
Cost of Revenue | 82.04 | 87.9 | 144.77 | 195.71 | 176.45 | 122.17 |
Gross Profit | 61.57 | 72.07 | 53.88 | 120.12 | 107.05 | 84.61 |
Selling, General & Admin | 115.7 | 115.89 | 141.71 | 154.68 | 144.74 | 139.2 |
Operating Expenses | 117.85 | 118.73 | 144.03 | 162.58 | 145.2 | 139.48 |
Operating Income | -56.29 | -46.66 | -90.15 | -42.47 | -38.15 | -54.86 |
Interest Expense | -10.21 | -10.11 | -7.43 | -21.65 | -17.14 | -31.85 |
Interest & Investment Income | 0.06 | 0.08 | 0.14 | 0.1 | 0.17 | 0.15 |
Earnings From Equity Investments | - | - | - | - | - | -24.46 |
Currency Exchange Gain (Loss) | -0.08 | 0.69 | 0.89 | 2.76 | -1.25 | -1.85 |
Other Non Operating Income (Expenses) | 7.39 | 6.49 | 4.3 | 5.16 | 10.35 | -3.03 |
EBT Excluding Unusual Items | -59.14 | -49.52 | -92.26 | -56.1 | -46.02 | -115.9 |
Gain (Loss) on Sale of Investments | 44.4 | -38.12 | -99.54 | -140.27 | -54.05 | -70.94 |
Gain (Loss) on Sale of Assets | -1.03 | -1.03 | -2.05 | -2.82 | -22.91 | 0.64 |
Asset Writedown | - | - | -78.75 | - | - | - |
Other Unusual Items | 0.26 | 0.31 | - | - | - | 14.22 |
Pretax Income | -15.52 | -88.37 | -272.59 | -199.18 | -122.97 | -171.98 |
Income Tax Expense | 0.01 | -0.33 | -0.02 | 3.47 | 0.97 | 0.01 |
Earnings From Continuing Operations | -15.54 | -88.04 | -272.57 | -202.66 | -123.94 | -171.99 |
Earnings From Discontinued Operations | 4.37 | - | - | - | - | - |
Net Income to Company | -11.17 | -88.04 | -272.57 | -202.66 | -123.94 | -171.99 |
Minority Interest in Earnings | -17.73 | -0.07 | 3.63 | 4.59 | 50.99 | 3.21 |
Net Income | -28.9 | -88.11 | -268.94 | -198.07 | -72.95 | -168.78 |
Net Income to Common | -28.9 | -88.11 | -268.94 | -198.07 | -72.95 | -168.78 |
Shares Outstanding (Basic) | 2,806 | 2,806 | 2,806 | 2,806 | 2,795 | 2,672 |
Shares Outstanding (Diluted) | 2,806 | 2,806 | 2,806 | 2,806 | 2,795 | 2,672 |
Shares Change (YoY) | - | - | - | 0.39% | 4.58% | 9.11% |
EPS (Basic) | -0.01 | -0.03 | -0.10 | -0.07 | -0.03 | -0.06 |
EPS (Diluted) | -0.01 | -0.03 | -0.10 | -0.07 | -0.03 | -0.06 |
Free Cash Flow | -49.19 | -53.54 | -14.95 | -39.3 | -217.32 | -140.86 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.01 | -0.01 | -0.08 | -0.05 |
Gross Margin | 42.87% | 45.05% | 27.12% | 38.03% | 37.76% | 40.92% |
Operating Margin | -39.20% | -29.17% | -45.38% | -13.45% | -13.46% | -26.53% |
Profit Margin | -20.12% | -55.08% | -135.39% | -62.71% | -25.73% | -81.62% |
Free Cash Flow Margin | -34.25% | -33.47% | -7.53% | -12.44% | -76.66% | -68.12% |
EBITDA | -43.03 | -33.35 | -71.41 | -30.25 | -34.44 | -49.94 |
EBITDA Margin | -29.97% | -20.85% | -35.95% | -9.58% | -12.15% | -24.15% |
D&A For EBITDA | 13.25 | 13.31 | 18.74 | 12.22 | 3.71 | 4.93 |
EBIT | -56.29 | -46.66 | -90.15 | -42.47 | -38.15 | -54.86 |
EBIT Margin | -39.20% | -29.17% | -45.38% | -13.45% | -13.46% | -26.53% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.